Clinical trials: Age-Related Maculopathy
Age-related Macular Degeneration
Reticular Pseudodrusen Progression Study
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial countries. Reticular pseudodrusen (RPD) have been recognized as an additional phenotypic characteristic frequently observed in…
- Trial name
- NCT02345317
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Muenster
The Injection Burden
Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept
The investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with AMD.
- Trial name
- NCT02126904
- Testing
- IVA group
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Yokohama City University Medical Center
Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
The goal of this clinical trial is to investigate the efficacy, durability, and safety of aflibercept 8 mg in treating Polypoidal Choroidal Vasculopathy (PCV) in Chinese naive patients.
- Trial name
- NCT07365371
- Testing
- Aflibercept Intravitreous Injection
- Where
- 20 sites in China
- Volunteers
- 174 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Age-Related Macular Degeneration
Ocular, Vascular, and Genetic Findings in AMD Patients
Observation of findings associated with AMD
- Trial name
- NCT06015633
- Testing
- No intervention
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- OcuDyne, Inc.
Neovascular Age-Related Macular Degeneration
A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration
This is a multicenter, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients with AMD.
- Trial name
- NCT03021785
- Testing
- TK001
- Where
- 5 sites in China
- Volunteers
- 36 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Wet Age-Related Macular Degeneration
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
This study evaluates the tolerability and safety of 3 months treatment with PTK787 tablets given daily. It also explores the efficacy of the compound in patients with wet age-related macular edema.
- Trial name
- ADVANCE (NCT00138632)
- Testing
- PTK787
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Novartis
Age-Related Macular Degeneration, Geographic Atrophy
Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study
This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition.
- Trial name
- CORE-GA (NCT07556406)
- Testing
- Optical coherence tomography, Microperimetry
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of California, San Francisco
Neovascular Age Related Macular Degeneration
Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
This study is designed to evaluate the effect of Visudyne® combination therapy (Visudyne® [verteporfin for injection] and Lucentis™) on visual acuity outcomes.
- Trial name
- Luvi (NCT00574093)
- Testing
- Ranibizumab; Verteporfin
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Age-Related Macular Degeneration
Treatment of Age-related Macular Degeneration Using Retinal Stem and Progenitor Cells
Treatment of age-related macular degeneration using retinal stem and progenitor cells
- Trial name
- NCT05187104
- Testing
- Cultured retinal stem and progenitor cells, Standard treatment according to the clinical protocols
- Where
- Belarus
- Volunteers
- 20 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Age Related Macular Degeneration
WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.
- Trial name
- NCT00992563
- Testing
- AL-39324 ophthalmic suspension, Ranibizumab 10 mg/mL
- Volunteers
- 35 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
Expressive Arts-based Intervention for Adults With Age-related Visual Impairment
Age-related Macular Degeneration (AMD) is an age-related eye disease resulting in vision loss. Persons with AMD not only experience a gradual loss of ability in independent living, but also profound impairment in psychosocial…
- Trial name
- NCT05675150
- Testing
- Expressive Arts-Based Intervention
- Where
- Hong Kong
- Volunteers
- 154 people
- Sponsor
- The University of Hong Kong
Wet Age-related Macular Degeneration
Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered daily over a 6-week dosing period in subjects with refractory wet age-related macular degeneration (wAMD).
- Trial name
- NCT03558074
- Testing
- ALK4290
- Where
- 5 sites in Hungary
- Volunteers
- 26 people
- Sponsor
- Alkahest, Inc.
Neovascular Age-related Macular Degeneration
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
This study is designed to evaluate the safety and efficacy of every 2 week intravitreal aflibercept injections in a population of neovascular AMD patients that have demonstrated refractory subretinal fluid with or without…
- Trial name
- TRISTAR (NCT03468296)
- Testing
- Intravitreal Aflibercept Injection 2mg
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Tennessee Retina
Age-Related Macular Degeneration
Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration
The investigators have developed an image analysis method that can predict the likelihood that a patient with age related macular degeneration (AMD) will progress within 1 year, based on computerized analysis of optical coherence…
- Trial name
- NCT02422160
- Testing
- No interventions are planned
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR)
Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment
This prospective interventional translational study aims to identify and validate protein biomarkers associated with major ophthalmological diseases, including age-related macular degeneration, diabetic retinopathy (DR), and…
- Conditions
- Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Retinal Detachment
- Trial name
- PRO Project (NCT07500324)
- Testing
- Biological Sample Collection
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Geographic Atrophy, Macular Degeneration
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
- Trial name
- NCT04435366
- Testing
- Avacincaptad Pegol
- Where
- 205 sites in United States, Argentina and 18 more
- Volunteers
- 448 people
- Sponsor
- IVERIC bio, Inc.
Neovascular Age-related Macular Degeneration
Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
This retrospective study included nAMD patients whose eyes were grouped into the following cohorts, with the overall cohort receiving ≥ 1 brolucizumab injection; the 12-month and 18-month brolucizumab (BRO) cohorts, which…
- Trial name
- NCT06178770
- Where
- United States
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration
A study evaluating Retisert in patients with age-related macular degeneration
- Trial name
- NCT00032396
- Testing
- Retisert Implant
- Where
- United States
- Sponsor
- Control Delivery Systems
Age Related Macular Degeneration
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration
The purpose of this research study is to determine if photobiomodulation is an effective treatment of Dry Age-Related Macular Degeneration (AMD) and vision loss associated with the disease.
- Trial name
- LIGHTSITE1 (NCT02725762)
- Testing
- LT-300 Active (PBM)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- LumiThera, Inc.
Macular Degeneration
High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration
This study will use an eye imaging test called high speed indocyanine green angiography (HS-ICG), which examines leaky vessels in the eye, to try to find out why individuals respond differently to ranibizumab (Lucentis) treatment…
- Trial name
- NCT00656903
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Eye Institute (NEI)